BILL ANALYSIS

SJRES136

NEUTRAL

A joint resolution providing for congressional disapproval of the proposed licensing of certain defense articles and services to Israel.

SJRES136 (A joint resolution providing for congressional disapproval of the proposed licensing of certain defense articles and services to Israel.) has been assessed with a neutral outlook for investors. The primary sectors impacted are Defense. View the full bill text on Congress.gov.

neutral

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

S.J. Res. 136 is procedurally stalled with no pathway to enactment — 4 junior sponsors, no House companion, no committee action since referral.

The blocked sale of 5,000 Small Diameter Bombs is immaterial to $LMT's $70B+ revenue base and has no impact on $RTX or $BA.

Real market data shows $LMT down 15.91% in 30 days — this is a macro defense sector move, not related to this resolution.

How SJRES136 Affects the Market

No market implications. This resolution is legislative noise. at $508.23, $RTX, and are trading on broader defense sector dynamics (budget negotiations, geopolitical shifts, earnings) — not on a stalled disapproval resolution with zero momentum. Investors should ignore this bill entirely for portfolio decisions.

Bill Details

Metric	Value
Bill Number	SJRES136
Market Sentiment	neutral
Event Date	March 19, 2026
Affected Sectors	Defense
Source	View on Congress.gov →

Summary

S.J. Res. 136 is an early-stage, low-momentum resolution to block a specific arms sale to Israel including 5,000 Small Diameter Bomb systems. With only 4 junior sponsors, no House companion, and referral to committee without further action, the bill has near-zero probability of enactment. Direct financial impact on $LMT, $RTX, and $BA is negligible.

Full AI Market Analysis

What happened: On March 19, 2026, Senator Sanders introduced S.J. Res. 136, a joint resolution of disapproval targeting a specific arms sale notification to Israel involving 5,000 Small Diameter Bomb Weapon Systems. The bill was read twice and referred to the Senate Committee on Foreign Relations. As of April 30, 2026, there have been no further actions — no hearings, markups, or votes. The resolution has 4 cosponsors, all junior members (Sanders, Van Hollen, Merkley, Welch), and no companion bill in the House. The money trail: This resolution does not authorize or appropriate any funding. It is a disapproval mechanism under the Arms Export Control Act. If enacted, it would block a specific sale but redirects no funds and creates no new spending. The value of the blocked 5,000 SDB systems is not specified in the bill text but represents a fraction of annual U.S. defense exports to Israel (~$3.8B in FY2025). Structural winners and losers: The resolution poses no structural threat to any defense prime. Lockheed Martin manufactures the SDB, but 5,000 units represent a negligible portion of its Missiles and Fire Control segment revenue ($17.8B in FY2025). Raytheon ($RTX) and Boeing have minimal to no direct exposure to this specific product line. Even if the resolution somehow advanced, the blocked sale would likely be offset by other arms packages or contract modifications. Real market data context: is trading at $508.23 as of April 30, 2026, down 15.91% over the past 30 days from a close of $592.19 on April 17. This decline is driven by broader defense sector headwinds — not this procedural resolution. $RTX and have seen similar macro-driven pressure. The resolution has had zero detectable impact on these price movements. Timeline: The bill remains in committee with no scheduled hearings. Congress typically has 30 days of continuous session to act on disapproval resolutions under the Arms Export Control Act; that window has passed without action. The practical path forward is effectively dead absent a dramatic shift in political support or a new arms notification that reopens the window.